|Bid||68.11 x 800|
|Ask||70.21 x 3000|
|Day's range||68.45 - 69.53|
|52-week range||26.49 - 77.49|
|Beta (5Y monthly)||1.40|
|PE ratio (TTM)||16.51|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.
Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.